IP Library Granted Patent US 10,435,479
Granted Patent B2
US 10,435,479 · App. 15/310,214 · Granted Oct 8, 2019

Chemically-locked bispecific antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,435,479
App. No.
15/310,214
Granted
Oct 8, 2019
Kind
B2
Abstract

There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the IgG class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific IgG class antibody having a linkage region joined together with bio-orthogonal click chemistry.

Claims (15)

1. A bi-specific antibody comprising:

(a) a first antibody fragment A′, comprising a single heavy chain and light chain from an antibody A, wherein the single heavy chain of the first antibody fragment A′ has one or two reactive thiol groups in the hinge region, and wherein antibody A is an IgG1, IgG2 or IgG4 class antibody; and

(b) a second antibody fragment B′, comprising a single heavy chain and light chain from an antibody B, wherein the single heavy chain of the second antibody fragment B′ has one or two reactive thiol groups in the hinge region, and wherein antibody B is an IgG1, IgG2 or IgG4 class antibody;

wherein said first antibody fragment A′ and second antibody fragment B′ are covalently linked through a 1,2,3-triazole formed by a cycloaddition reaction of an azide and an alkyne;

wherein the azide is attached through a linker to the one or two reactive thiol groups on said first antibody fragment A′;

wherein the alkyne is attached through a linker to the one or two reactive thiol groups on said second antibody fragment B′; and

wherein the alkyne together with the attached linker has the structure:

2. The bi-specific antibody of claim 1 , wherein the azide, together with the attached linker, is selected from:

3. A pharmaceutical formulation comprising an effective amount of the bispecific antibody of claim 1 in an aqueous solution suitable for human use.

4. The bispecific antibody of claim 1 , wherein A′ is linked through a reactive thiol group in the hinge region to a moiety having the structure:

5. The bispecific antibody of claim 1 , wherein A′ and B′ have a hinge residue sequence CPPC (SEQ ID NO:1), or CPSC (SEQ ID NO:2), or SPPC (SEQ ID NO:3), or SPSC (SEQ ID NO:4) (EU-index numbering: residues 226-229; Kabat numbering: residues 239-242).

6. The chemically locked bispecific antibody of claim 1 , having the formula:

7. The bispecific antibody of claim 1 , wherein A and B are IgG1 class antibodies.

8. The bispecific antibody of claim 1 , wherein A and B are IgG4 immunoglobulins with hinge mutations S PSC.

9. The bispecific antibody of claim 1 , wherein A is an anti-cMet antibody and B is an anti-PD-L1 antibody.

Assignments (7)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 053368/0577 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: FU, YANWEN; KAUFMANN, GUNNAR F.; JONES, BRYAN; TOUGHIRI, RAHELEH
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 050193/0422 →
SECURITY INTEREST Recorded Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →